Alcon Inc. (ALC)
| Market Cap | 36.92B -19.3% |
| Revenue (ttm) | 10.40B +4.9% |
| Net Income | 980.00M -3.7% |
| EPS | 1.98 -3.4% |
| Shares Out | 487.43M |
| PE Ratio | 37.67 |
| Forward PE | 21.58 |
| Dividend | $0.22 (0.29%) |
| Ex-Dividend Date | May 14, 2025 |
| Volume | 1,719,826 |
| Open | 76.85 |
| Previous Close | 77.78 |
| Day's Range | 75.74 - 77.01 |
| 52-Week Range | 71.55 - 99.20 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 89.38 (+18.01%) |
| Earnings Date | Feb 24, 2026 |
About ALC
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS... [Read more]
Financial Performance
In 2025, Alcon's revenue was $10.40 billion, an increase of 4.94% compared to the previous year's $9.91 billion. Earnings were $980.00 million, a decrease of -3.73%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ALC stock is "Buy." The 12-month stock price target is $89.38, which is an increase of 18.01% from the latest price.
News
LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review
LENSAR Inc. (NASDAQ: LNSR) shares are down during Tuesday’s premarket session following the termination of a merger agreement with Alcon AG (NYSE: ALC). In March 2025, Alcon agreed to acquire the la...
Alcon Buy Rating Reaffirmed, Despite Failed STAAR Merger, As Eyecare Portfolio Leads
Alcon is reaffirmed as a buy, supported by robust macro demand in eyecare and a strong product pipeline despite abandoning the STAAR Surgical acquisition. ALC demonstrates potential resilience versus ...
Lensar (LNSR) and Alcon (ALC) Terminate Merger Agreement Amid FTC Concerns
Lensar (LNSR) and Alcon (ALC) Terminate Merger Agreement Amid FTC Concerns
Alcon (ALC) and Lensar Call Off Merger Agreement
Alcon (ALC) and Lensar Call Off Merger Agreement
Alcon (ALC) Ends Merger Talks with Lensar, Impacting Both Stocks
Alcon (ALC) Ends Merger Talks with Lensar, Impacting Both Stocks
Alcon Ends Merger Agreement With LENSAR After FTC Opposition
(RTTNews) - Alcon Inc. (ALC) announced on Monday that it has agreed with LENSAR, Inc. (LNSR) to terminate their previously announced merger agreement.
Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement
GENEVA--(BUSINESS WIRE)--Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement.
LENSAR Announces Termination of Merger Agreement with Alcon Research, LLC
Company to Report Fourth Quarter Financial Results and Provide Strategic Update on March 31, 2026 ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Compan...
Glaucoma Research Foundation and Alcon Partner to Expand Access to Trusted Glaucoma Education
New English and Spanish editions of Understanding and Living with Glaucoma and first-ever Spanish audiobook aim to reach high-risk Hispanic communities Resources will be available during Glaucoma Awar...
Stifel Raises Alcon (ALC) Price Target to $82, Maintains 'Hold' Rating | ALC Stock News
Stifel Raises Alcon (ALC) Price Target to $82, Maintains 'Hold' Rating | ALC Stock News
Alcon Earnings Report: Q4 Overview
Alcon (NYSE: ALC) reported its Q4 earnings results on Tuesday, February 24, 2026 at 04:30 PM. Here's what investors need to know about the announcement. Earnings Alcon missed estimated earnings by -7...
Alcon Inc (ALC) Stock Price Down 3.54% on Mar 2
Alcon Inc (ALC) Stock Price Down 3.54% on Mar 2
Alcon Surpasses 175 Million IOLs Implanted Globally
GENEVA--(BUSINESS WIRE)--Alcon Surpasses 175 Million IOLs Implanted Globally.
Alcon Surpasses 175 Million IOLs Implanted Globally
Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announced that more than 175 million of its intraocular lenses (IOLs) have been implanted worldwide.9,+ ...
Barclays Maintains Rating for Alcon (ALC) and Raises Price Target | ALC Stock News
Barclays Maintains Rating for Alcon (ALC) and Raises Price Target | ALC Stock News
Today's Analyst Upgrade for Alcon (ALC) with New Price Target | ALC Stock News
Today's Analyst Upgrade for Alcon (ALC) with New Price Target | ALC Stock News
Alcon (ALC) Receives Upgrade as Growth Prospects Brighten
Alcon (ALC) Receives Upgrade as Growth Prospects Brighten
LENSAR Provides Update on Pending Acquisition by Alcon
ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...
Alcon (ALC) Reports Strong Q4 2025 Performance with 7% Sales Growth
Alcon (ALC) Reports Strong Q4 2025 Performance with 7% Sales Growth
Alcon Inc (ALC) (Full Year 2025) Earnings Call Highlights: Strong Revenue Growth Amid Market ...
Alcon Inc (ALC) (Full Year 2025) Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges
Alcon Inc. (ALC) Q4 2025 Earnings Call Transcript
Alcon Inc. (ALC) Q4 2025 Earnings Call Transcript
Full Year 2025 Alcon AG Earnings Call Transcript
Full Year 2025 Alcon AG Earnings Call Transcript
Alcon Inc (ALC) Stock Price Up 3.55% on Feb 25
Alcon Inc (ALC) Stock Price Up 3.55% on Feb 25
Alcon (ALC) Receives New "Buy" Rating and Raised Price Target from BTIG | ALC Stock News
Alcon (ALC) Receives New "Buy" Rating and Raised Price Target from BTIG | ALC Stock News
Alcon (ALC) Q4 2025 Earnings Call Transcript
Alcon (ALC) Q4 2025 Earnings Call Transcript